6.
Yahalom J, Illidge T, Specht L, Hoppe R, Li Y, Tsang R
. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015; 92(1):11-31.
DOI: 10.1016/j.ijrobp.2015.01.009.
View
7.
Fassas A, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E
. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002; 117(1):103-8.
DOI: 10.1046/j.1365-2141.2002.03401.x.
View
8.
Wirth A, George Mikhaeel N, Aleman B, Pinnix C, Constine L, Ricardi U
. Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. Int J Radiat Oncol Biol Phys. 2020; 107(5):909-933.
DOI: 10.1016/j.ijrobp.2020.03.019.
View
9.
Tringale K, Scordo M, Yahalom J, White C, Zhang Z, Vachha B
. Outcomes and relapse patterns in primary central nervous system lymphoma: Longitudinal analysis of 559 patients diagnosed from 1983 to 2020. Neuro Oncol. 2024; 26(11):2061-2073.
PMC: 11534311.
DOI: 10.1093/neuonc/noae115.
View
10.
Frigault M, Dietrich J, Martinez-Lage M, Leick M, Choi B, DeFilipp Z
. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019; 134(11):860-866.
PMC: 7022436.
DOI: 10.1182/blood.2019001694.
View
11.
Siddiqi T, Wang X, Blanchard M, Wagner J, Popplewell L, Budde L
. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021; 5(20):4059-4063.
PMC: 8945630.
DOI: 10.1182/bloodadvances.2020004106.
View
12.
Klanova M, Sehn L, Bence-Bruckler I, Cavallo F, Jin J, Martelli M
. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019; 133(9):919-926.
PMC: 6396175.
DOI: 10.1182/blood-2018-07-862862.
View
13.
Chen C, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda V
. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013; 162(4):483-8.
DOI: 10.1111/bjh.12414.
View
14.
Poortmans P, Kluin-Nelemans H, Haaxma-Reiche H, Veer M, Hansen M, Soubeyran P
. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003; 21(24):4483-8.
DOI: 10.1200/JCO.2003.03.108.
View
15.
Ebadi M, Morse M, Gooley T, Ermoian R, Halasz L, Lo S
. Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control. J Neurooncol. 2024; 166(2):351-357.
DOI: 10.1007/s11060-023-04501-5.
View
16.
Nelson D, Martz K, Bonner H, Nelson J, NEWALL J, KERMAN H
. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992; 23(1):9-17.
DOI: 10.1016/0360-3016(92)90538-s.
View
17.
Sancho J, Ribera J, Oriol A, Hernandez-Rivas J, Rivas C, Bethencourt C
. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006; 106(12):2540-6.
DOI: 10.1002/cncr.21948.
View
18.
Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M
. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2015; 42(3):279-90.
DOI: 10.1111/nan.12259.
View
19.
Ollila T, Kurt H, Waroich J, Vatkevich J, Sturtevant A, Patel N
. Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma. Blood. 2020; 137(8):1120-1124.
PMC: 8215190.
DOI: 10.1182/blood.2020007236.
View
20.
OBrien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M
. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000; 18(3):519-26.
DOI: 10.1200/JCO.2000.18.3.519.
View